TransMedics Group Target of Unusually Large Options Trading (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) saw some unusual options trading on Monday. Investors bought 15,600 put options on the stock. This is an increase of approximately 603% compared to the typical daily volume of 2,219 put options.

TransMedics Group Price Performance

TMDX opened at $75.48 on Tuesday. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The business’s fifty day simple moving average is $85.70 and its 200-day simple moving average is $114.51. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of 17.15 and a beta of 1.92.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. During the same period in the previous year, the company posted $0.70 EPS. TransMedics Group’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, equities research analysts anticipate that TransMedics Group will post 1.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. JPMorgan Chase & Co. upped their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Stifel Nicolaus cut their price objective on TransMedics Group from $85.00 to $75.00 and set a “hold” rating on the stock in a research report on Tuesday, May 26th. Needham & Company LLC cut their price objective on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, TD Cowen cut their price objective on TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group currently has a consensus rating of “Hold” and an average price target of $134.00.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently made changes to their positions in the business. D.A. Davidson & CO. increased its position in shares of TransMedics Group by 0.5% during the fourth quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after purchasing an additional 83 shares in the last quarter. Parallel Advisors LLC raised its stake in TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after buying an additional 83 shares during the last quarter. HighPoint Advisor Group LLC raised its stake in TransMedics Group by 3.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after buying an additional 88 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in TransMedics Group by 4.0% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock valued at $277,000 after buying an additional 88 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in TransMedics Group by 2.9% in the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after buying an additional 100 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.